

CITATION REPORT

List of articles citing

Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults

DOI: 10.3233/jad-2008-13309

Journal of Alzheimer s Disease, 2008, 13, 323-31.

Source: <https://exaly.com/paper-pdf/44919711/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
435	From nose to brain: understanding transport capacity and transport rate of drugs. 2008 , 5, 1159-68		112
434	Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. 2008 , 9 Suppl 3, S5		399
433	Towards non invasive nerve growth factor therapies for Alzheimer's disease. <i>Journal of Alzheimers Disease</i> , 2008 , 15, 255-83	4.3	79
432	Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial. 2009 , 46, 217-22		37
431	Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. 2009 , 330, 679-86		147
430	Therapy for Alzheimer's Disease: How Effective are Current Treatments?. 2009 , 2, 163-80		69
429	The 6th Annual World Congress on the Insulin Resistance Syndrome. 2009 , 32, e127-33		5
428	Mediterranean diet and mild cognitive impairment. 2009 , 66, 216-25		438
427	Characteristics of compounds that cross the blood-brain barrier. 2009 , 9 Suppl 1, S3		378
426	Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. 2009 , 98, 2501-15		84
425	Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders?. 2009 , 52, 2264-9		72
424	The transnasal delivery of 5-fluorouracil to the rat brain is enhanced by acetazolamide (the inhibitor of the secretion of cerebrospinal fluid). 2009 , 377, 85-91		20
423	Proteins and Peptides. 2009 ,		5
422	Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. 2009 , 284, 18742-53		109
421	Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. 2009 , 1792, 482-96		231
420	The chemistry of Alzheimer's disease. 2009 , 38, 2698-715		339
419	Early risk assessment for Alzheimer's disease. 2009 , 5, 182-96		33

418	Senescence of the brain: focus on cognitive kinases. 2010 , 16, 660-71		41
417	Chromosome 22q13 Rearrangements Causing Global Developmental Delay and Autistic Spectrum Disorder. 2010 , 137-150		2
416	Transnasal delivery of methotrexate to brain tumors in rats: a new strategy for brain tumor chemotherapy. 2010 , 7, 1561-8		46
415	HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. 2010 , 5, 294-309		171
414	Intranasal delivery to the central nervous system: mechanisms and experimental considerations. 2010 , 99, 1654-73		756
413	Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. 2010 , 99, 1745-61		75
412	Presenilin-1 regulates induction of hypoxia inducible factor-1 β altered activation by a mutation associated with familial Alzheimer's disease. 2010 , 5, 38		24
411	The Nuclear Receptor PPAR γ as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. 2010 , 2,		42
410	Vascular pharmacotherapy and dementia. 2010 , 8, 44-50		2
409	Intranasal delivery of calcitonin gene-related peptide reduces cerebral vasospasm in rats. 2010 , 2, 1502-13		16
408	GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 19, 1205-19	4-3	233
407	Diabetes and the Brain. 2010 ,		3
406	The inositol phosphatase SHIP2 negatively regulates insulin/IGF-I actions implicated in neuroprotection and memory function in mouse brain. 2010 , 24, 1965-77		31
405	The Brain-insulin Connection, Metabolic Diseases and Related Pathologies. 2010 , 21-42		4
404	Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. <i>Journal of Alzheimer's Disease</i> , 2010 , 20 Suppl 2, S439-52	4-3	91
403	Dietary trans-fat combined with monosodium glutamate induces dyslipidemia and impairs spatial memory. 2010 , 99, 334-42		23
402	PKC and Insulin Pathways in Memory Storage: Targets for Synaptogenesis, Anti-apoptosis, and the Treatment of AD. 2010 , 153-182		1
401	Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. 2010 , 7, 884-93		99

400	Diabetes, Insulin and Alzheimer's Disease. 2010 ,		2
399	The role of GLP-1 in neuronal activity and neurodegeneration. 2010 , 84, 331-54		47
398	Drug penetration across the blood-brain barrier: an overview. 2010 , 1, 535-62		20
397	Erythropoietin in stroke: quo vadis. 2010 , 10, 937-49		23
396	Various drug delivery approaches to the central nervous system. 2010 , 7, 113-35		29
395	Intranasal delivery of therapeutic proteins for neurological diseases. 2011 , 8, 1277-96		49
394	What was lost in translation in the DHA trial is whom you should intend to treat. 2011 , 3, 2		16
393	Insulin dysfunction and allostatic load in bipolar disorder. 2011 , 11, 1017-28		41
392	Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. 2011 , 39, 891-7		116
391	Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. 2011 , 103, 59-68		45 ^o
390	Dementia, diabetes, Alzheimer's disease, and insulin resistance in the brain: progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics. <i>Journal of Alzheimer's Disease</i> , 2011 , 25, 29-41	4.3	43
389	Nasal drug delivery in humans. 2011 , 40, 20-35		109
388	Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. 2011 , 19, 731-40		16
387	Intranasal delivery of stem cells to the brain. 2011 , 8, 623-32		67
386	The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. 2011 , 96, 529-43		314
385	Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. 2011 , 96, 432-42		137
384	Reprint of: 'Brain insulin signaling: A key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes'. 2011 , 96, 517-28		15
383	Protective Roles of the Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Hormones in Neurodegeneration. 2011 ,		

382	Chronic intranasal treatment with an anti-A β (30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. 2011 , 6, e18296		55
381	The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS. 2011 , 6, e18711		35
380	Nasal delivery of P-gp substrates to the brain through the nose-brain pathway. 2011 , 26, 248-55		14
379	ABCA1, apoE and apoA-I as potential therapeutic targets for treating Alzheimer's disease. 2011 , 1, 245-259		
378	Re-formulating drugs and vaccines for intranasal delivery: maximum benefits for minimum risks?. 2011 , 16, 4-7		5
377	Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. 2011 , 46, 112-5		117
376	[Diabetes mellitus and cognitive decline]. 2011 , 161, 524-30		4
375	Unconditioned and conditioned effects of intranasally administered insulin vs placebo in healthy men: a randomised controlled trial. 2011 , 54, 1502-6		28
374	Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?. 2011 , 19, 253-65		37
373	Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. 2011 , 225, 54-62		327
372	Glucose enhancement of human memory: a comprehensive research review of the glucose memory facilitation effect. <i>Neuroscience and Biobehavioral Reviews</i> , 2011 , 35, 770-83	9	100
371	Insulin suppresses the expression of amyloid precursor protein, presenilins, and glycogen synthase kinase-3beta in peripheral blood mononuclear cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 1783-8	5.6	14
370	Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study. 2011 , 34, 1766-70		96
369	Pancreatic function, type 2 diabetes, and metabolism in aging. 2012 , 2012, 320482		74
368	Relation between insulin, insulin-related factors, and plasma amyloid beta peptide levels at midlife in a population-based study. 2012 , 26, 50-4		9
367	Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment: a pilot clinical trial. 2012 , 69, 29-38		882
366	Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. 2012 , 64, 1004-26		54
365	Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. 2012 , 20, 829-39		113

364	Insulin promotes neuronal survival via the alternatively spliced protein kinase CKII isoform. 2012 , 287, 9299-310		60
363	Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. 2012 , 9, 35-66		301
362	Roles of Glucagon-Like Peptide and Glucose-Dependent Insulinotropic Polypeptide Hormones in Brain Function and Neurodegeneration. 2012 , 351-373		
361	.		2
360	Metabolic reserve as a determinant of cognitive aging. <i>Journal of Alzheimer's Disease</i> , 2012 , 30 Suppl 2, S5-13	4.3	33
359	Drug repositioning for Alzheimer's disease. 2012 , 11, 833-46		191
358	Insulin to treat Alzheimer's disease: just follow your nose?. 2012 , 5, 17-20		16
357	Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins. 2012 , 36, 168-75		55
356	Amyloid- β protein modulates insulin signaling in presynaptic terminals. 2012 , 37, 1879-85		31
355	Effect of intranasal insulin on cognitive function: a systematic review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 366-76	5.6	118
354	Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway. 2012 , 513, 193-7		41
353	A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. 2012 , 14, 697-706		64
352	The role of glucose transporters in brain disease: diabetes and Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 12629-55	6.3	150
351	Brain meets body: the blood-brain barrier as an endocrine interface. 2012 , 153, 4111-9		99
350	Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. 2012 , 72, 49-66		150
349	Intranasal delivery of growth differentiation factor 5 to the central nervous system. 2012 , 19, 149-54		25
348	Insulin in the brain: there and back again. 2012 , 136, 82-93		340
347	Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. 2012 , 26, 871-82		122

346	The cerebrospinal fluid: regulator of neurogenesis, behavior, and beyond. 2012 , 69, 2863-78		108
345	Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. 2012 , 4, 1582-605		35
344	Insulin: an emerging treatment for Alzheimer's disease dementia?. 2012 , 12, 520-7		45
343	Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. <i>Journal of Alzheimer's Disease</i> , 2012 , 30 Suppl 2, S199-215	4-3	56
342	Brain insulin signaling and Alzheimer's disease: current evidence and future directions. 2012 , 46, 4-10		129
341	Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. 2012 , 64, 629-39		113
340	Intranasal administration of nerve growth factor ameliorate Amyloid deposition after traumatic brain injury in rats. 2012 , 1440, 47-55		59
339	Role of the blood-brain barrier in the evolution of feeding and cognition. 2012 , 1264, 13-9		54
338	Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. 2012 , 14, 214-21		91
337	Differential effects of intranasal insulin and caffeine on cerebral blood flow. 2012 , 33, 280-7		20
336	Metabolic Syndrome. 2013 ,		24
335	Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. 2013 , 108, 21-43		368
334	Brain insulin and leptin signaling in metabolic control: from animal research to clinical application. 2013 , 42, 109-25		10
333	Therapeutic effect of exogenous hsp70 in mouse models of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2014 , 38, 425-35	4-3	87
332	Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. 2013 , 27, 505-14		329
331	Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2013 , 35, 789-97	4-3	141
330	Insulin, cognition, and dementia. 2013 , 719, 170-179		132
329	The Janus Face of Insulin in Brain. 2013 , 85-113		

328	APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease. 2013 , 34, 1007-17	51
327	Type 2 diabetes and cognitive compromise: potential roles of diabetes-related therapies. 2013 , 42, 489-501	33
326	Insulin in the brain: sources, localization and functions. 2013 , 47, 145-71	180
325	Intranasal treatment of central nervous system dysfunction in humans. 2013 , 30, 2475-84	197
324	The olfactory system in Alzheimer's disease: Pathology, pathophysiology and pathway for therapy. 2013 , 4,	13
323	A review: treatment of Alzheimer's disease discovered in repurposed agents. 2013 , 35, 1-22	59
322	Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. <i>Neurochemistry International</i> , 2013 , 62, 165-72	4.4 121
321	Insulin and the Brain. 2013 , 9, 102-116	7
320	Intranasal Drug Delivery to the Central Nervous System: Present Status and Future Outlook. 2013 , 19, 510-526	27
319	Cinnamon counteracts the negative effects of a high fat/high fructose diet on behavior, brain insulin signaling and Alzheimer-associated changes. 2013 , 8, e83243	46
318	Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. 2013 , 6, 1304-21	33
317	New animal models of Alzheimer's disease that display insulin desensitization in the brain. 2013 , 24, 607-15	26
316	Routes of Delivery for Biological Drug Products. 2013 , 1-48	3
315	Intranasal insulin therapy for cognitive impairment and neurodegeneration: current state of the art. 2013 , 10, 1699-709	51
314	Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer's Disease. 2013 , 11, 102-8	39
313	Diseases Mediated by the BBB: Alzheimer's, Obesity, and Beyond. 2013 , 1667-1671	
312	CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer's Disease. 2013 , 3, 128	25
311	Neuronal Insulin Receptor Signaling: A Potential Target for the Treatment of Cognitive and Mood Disorders. 2013 ,	4

310	Emerging Trends in Noninvasive Insulin Delivery. 2014 , 2014, 378048	17
309	Intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in 3xTg-AD mice. 2014 , 6, 100	34
308	Insulin dysfunction and Tau pathology. 2014 , 8, 22	76
307	Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. 2014 , 6, 57	52
306	The Potential Role of Insulin on the Shank-Postsynaptic Platform in Neurodegenerative Diseases Involving Cognition. 2014 , 29, 303-10	2
305	Oligomeric A β induced synaptic dysfunction in Alzheimer's disease. 2014 , 9, 48	308
304	A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. 2014 , 28, 1185-9	36
303	Obesity, Western Diet Intake, and Cognitive Impairment. 2014 , 57-62	1
302	Insulin resistance, neuroinflammation, and Alzheimer's disease. 2014 , 25, 509-25	39
301	Therapeutics of Alzheimer's disease: Past, present and future. 2014 , 76 Pt A, 27-50	477
300	Mechanisms of action of brain insulin against neurodegenerative diseases. 2014 , 121, 611-26	19
299	Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. 2014 , 14, 476	102
298	Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice. 2014 , 49, 547-62	59
297	Neuropathology of type 2 diabetes: a short review on insulin-related mechanisms. 2014 , 24, 1961-6	7
296	Cognitive and motor perturbations in elderly with longstanding diabetes mellitus. 2014 , 30, 628-35	17
295	Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. 2014 , 221, T31-41	191
294	Intranasal administration as a route for drug delivery to the brain: evidence for a unique pathway for albumin. 2014 , 351, 54-60	50
293	Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases. 2014 , 42, 593-9	69

292	Insulin induces phosphorylation of the AMPA receptor subunit GluR1, reversed by ZIP, and over-expression of Protein Kinase M zeta, reversed by amyloid beta. 2014 , 131, 582-7		30
291	Precision nanomedicine in neurodegenerative diseases. 2014 , 8, 1958-65		70
290	Deregulation of brain insulin signaling in Alzheimer's disease. 2014 , 30, 282-94		58
289	Intranasal therapeutic strategies for management of Alzheimer's disease. 2014 , 22, 279-94		57
288	Insulin and insulin-like growth factor receptors in the brain: physiological and pathological aspects. 2014 , 24, 1947-53		109
287	Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?. 2014 , 118, 1-18		143
286	First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease. 2014 , 10, S33-7		49
285	Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. 2014 , 37, 751-9		127
284	Insulin protects against A β -induced spatial memory impairment, hippocampal apoptosis and MAPKs signaling disruption. 2014 , 85, 113-20		45
283	Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces A β level and microglia activation in the brains of 3xTg-AD mice. 2014 , 261, 610-9		74
282	Intranasal insulin: is there a promise for treatment of diabetes-related cognitive decline?. 2014 , 4, 315-317		
281	Alzheimer's Disease: Mechanism and Approach to Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 26417-51	6.3	66
280	Shared Neuropathological Characteristics of Obesity, Type 2 Diabetes and Alzheimer's Disease: Impacts on Cognitive Decline. 2015 , 7, 7332-57		78
279	Can insulin signaling pathways be targeted to transport A β out of the brain?. 2015 , 7, 114		20
278	Aberrant insulin signaling in Alzheimer's disease: current knowledge. <i>Frontiers in Neuroscience</i> , 2015 , 9, 204	5.1	178
277	Insulin Regulates the Activity of the High-Affinity Choline Transporter CHT. 2015 , 10, e0132934		7
276	Unaltered Prion Pathogenesis in a Mouse Model of High-Fat Diet-Induced Insulin Resistance. 2015 , 10, e0144983		12
275	Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer's Disease. 2015 , 2015, 105828		263

274	Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. 2015 , 47, e149	167
273	Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke. 2015 , 6, 264-75	63
272	Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities. 2015 , 12, 66-80	49
271	Metformin increases APP expression and processing via oxidative stress, mitochondrial dysfunction and NF- κ B activation: Use of insulin to attenuate metformin's effect. 2015 , 1853, 1046-59	74
270	The metabolism hypothesis of Alzheimer's disease: from the concept of central insulin resistance and associated consequences to insulin therapy. 2015 , 122, 499-504	28
269	daf-16/FOXO and glod-4/glyoxalase-1 are required for the life-prolonging effect of human insulin under high glucose conditions in <i>Caenorhabditis elegans</i> . 2015 , 58, 393-401	26
268	Solid microparticles based on chitosan or methyl- β -cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. 2015 , 201, 68-77	91
267	Western Diet and Cognitive Impairment. 2015 , 295-305	3
266	Intranasal delivery: circumventing the iron curtain to treat neurological disorders. 2015 , 12, 1717-25	28
265	Hippocampal Insulin Resistance Impairs Spatial Learning and Synaptic Plasticity. 2015 , 64, 3927-36	170
264	Enhanced memory consolidation in mice lacking the circadian modulators Sharp1 and -2 caused by elevated Igf2 signaling in the cortex. 2015 , 112, E3582-9	19
263	Intranasal Neuropeptide Administration To Target the Human Brain in Health and Disease. 2015 , 12, 2767-80	29
262	The role of type 2 diabetes in neurodegeneration. 2015 , 84, 22-38	163
261	Ketamine modulates TRH and TRH-like peptide turnover in brain and peripheral tissues of male rats. 2015 , 69, 66-76	12
260	Signaling Pathways Involved in Cognitive Enhancement. 2015 , 11-42	1
259	Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models. 2015 , 31, 1-13	47
258	Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia. 2016 , 22, 812-8	45
257	The Rationale for Insulin Therapy in Alzheimer's Disease. 2016 , 21,	11

256	Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood. 2016 , 5, 589-601	91
255	Alzheimer's disease: Is this a brain specific diabetic condition?. 2016 , 164, 259-67	32
254	Diabetes mellitus and Alzheimer's disease: An unforgettable relation. 2016 , 63, 191-193	1
253	Sex biology contributions to vulnerability to Alzheimer's disease: A think tank convened by the Women's Alzheimer's Research Initiative. 2016 , 12, 1186-1196	106
252	Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration. 2016 , 36, 10683-10695	48
251	Insulin resistance and Parkinson's disease: A new target for disease modification?. 2016 , 145-146, 98-120	138
250	Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease. 2016 , 241, 1676-83	27
249	Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans. 2016 , 96, 1169-209	251
248	Neonatal maternal separation stress elicits lasting DNA methylation changes in the hippocampus of stress-reactive Wistar Kyoto rats. 2016 , 44, 2829-2845	31
247	Type 2 Diabetes, Cognition, and Dementia in Older Adults: Toward a Precision Health Approach. 2016 , 29, 210-219	39
246	Pragmatic function impairment and Alzheimer's dementia. 2016 , 23, 324-342	1
245	Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease ¹ . <i>Journal of Alzheimer's Disease</i> , 2016 , 51, 961-77	4-3 40
244	Type 2 Diabetes, Obesity, and Risk for Dementia: Recent Insights into Brain Insulin Resistance and Hypometabolism. 2016 , 3, 293-300	3
243	Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide analogues as novel treatments for Alzheimer's and Parkinson's disease. 2016 , 5, 93-98	22
242	Insulin potentiates the therapeutic effect of memantine against central STZ-induced spatial learning and memory deficit. 2016 , 311, 247-254	9
241	Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence. 2016 , 30, 773-89	66
240	Cognitive impairment and pragmatics. 2016 , 5, 127	6
239	Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats. 2016 , 318, 157-65	47

238	Inside the Diabetic Brain: Role of Different Players Involved in Cognitive Decline. 2016 , 7, 131-42	72
237	From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. 2016 , 15, 275-92	534
236	Apolipoprotein E and Amyloid- β Independent Mechanisms in Alzheimer's Disease. 2016 , 171-196	1
235	Diabetes mellitus and Alzheimer's disease: An unforgettable relation. 2016 , 63, 191-3	3
234	Cognitively impaired elderly exhibit insulin resistance and no memory improvement with infused insulin. 2016 , 39, 19-24	21
233	Therapeutic strategies for Alzheimer's disease in clinical trials. 2016 , 68, 127-38	298
232	Central Nervous Insulin Signaling in Sleep-Associated Memory Formation and Neuroendocrine Regulation. 2016 , 41, 1540-50	21
231	Intranasal Insulin Improves Age-Related Cognitive Deficits and Reverses Electrophysiological Correlates of Brain Aging. 2016 , 71, 30-9	54
230	A stepped wedge design for testing an effect of intranasal insulin on cognitive development of children with Phelan-McDermid syndrome: A comparison of different designs. 2017 , 26, 766-775	8
229	Insulin and the Brain: A Sweet Relationship With Intensive Care. 2017 , 32, 48-58	14
228	Impact of Single or Repeated Dose Intranasal Zinc-free Insulin in Young and Aged F344 Rats on Cognition, Signaling, and Brain Metabolism. 2017 , 72, 189-197	21
227	Altered cerebral insulin response in transgenic mice expressing the epsilon-4 allele of the human apolipoprotein E gene. 2017 , 77, 203-210	7
226	Obesity and insulin resistance are associated with reduced activity in core memory regions of the brain. 2017 , 96, 137-149	67
225	Intranasal insulin treatment of an experimental model of moderate traumatic brain injury. 2017 , 37, 3203-3218	37
224	The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid- β , Amylin, and Tau Proteins. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 421-432	4-3 108
223	Intranasal Delivery of A Novel Amnion Cell Secretome Prevents Neuronal Damage and Preserves Function In A Mouse Multiple Sclerosis Model. 2017 , 7, 41768	22
222	Multiple functions of insulin-degrading enzyme: a metabolic crosslight?. 2017 , 52, 554-582	49
221	Insulin signaling: An opportunistic target to minimize the risk of Alzheimer's disease. 2017 , 83, 159-171	44

220	Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 193-201	4-3	9
219	Central Regulation of Glucose Homeostasis. 2017 , 7, 741-764		37
218	The SAMP8 mouse for investigating memory and the role of insulin in the brain. 2017 , 94, 64-68		9
217	Insulin resistance in Alzheimer's disease. 2017 , 183, 26-40		64
216	Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease. 2017 , 77, 47-65		144
215	Interactions between metabolic, reward and cognitive processes in appetite control: Implications for novel weight management therapies. 2017 , 31, 1460-1474		35
214	Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. 2017 , 96, 115-129.e5		138
213	Novel calcium-related targets of insulin in hippocampal neurons. 2017 , 364, 130-142		13
212	The relationship between obesity and cognitive health and decline. 2017 , 76, 443-454		137
211	Progress in brain targeting drug delivery system by nasal route. 2017 , 268, 364-389		167
210	Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults. 2017 , 7, 9766		38
209	Amyloid beta: structure, biology and structure-based therapeutic development. 2017 , 38, 1205-1235		492
208	Differential effects of blood insulin and HbA1c on cerebral amyloid burden and neurodegeneration in nondiabetic cognitively normal older adults. 2017 , 59, 15-21		13
207	Colloids for drug delivery to the brain. 2017 , 42, 193-206		8
206	Intranasal insulin enhances brain functional connectivity mediating the relationship between adiposity and subjective feeling of hunger. 2017 , 7, 1627		41
205	Calcium's role as nuanced modulator of cellular physiology in the brain. 2017 , 483, 981-987		21
204	The neuronal insulin receptor in its environment. 2017 , 140, 359-367		37
203	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 61, 309-320	4-3	19

202	A Brief Review of Caprylidene (Axona) and Coconut Oil as Alternative Fuels in the Fight Against Alzheimer's Disease. 2017 , 32, 748-751	1
201	Insulin and the Brain. 2017 , 24, 377-384	1
200	Sevoflurane Induces Exaggerated and Persistent Cognitive Decline in a Type II Diabetic Rat Model by Aggregating Hippocampal Inflammation. 2017 , 8, 886	18
199	βAmyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View. 2017 , 22,	62
198	Intranasal Insulin Prevents Anesthesia-Induced Cognitive Impairment and Chronic Neurobehavioral Changes. 2017 , 9, 136	20
197	Insulin Resistance and Alzheimer's Disease: Bioenergetic Linkages. 2017 , 9, 345	123
196	Challenges of the Nose-to-Brain Route. 2017 , 103-113	
195	Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives. 2017 , 2017, 7420796	28
194	Alzheimer's Disease: Dawn of a New Era?. 2017 , 20, 184-225	12
193	Safety of intranasal human insulin: A review. 2018 , 20, 1563-1577	52
192	Brain insulin signalling, glucose metabolism and females' reproductive aging: A dangerous triad in Alzheimer's disease. 2018 , 136, 223-242	26
191	Protective effects of the angiotensin II AT receptor agonist compound 21 in ischemic stroke: a nose-to-brain delivery approach. 2018 , 132, 581-593	15
190	Insulin receptor in the brain: Mechanisms of activation and the role in the CNS pathology and treatment. 2018 , 24, 763-774	68
189	Disturbed sleep and diabetes: A potential nexus of dementia risk. 2018 , 84, 85-93	21
188	Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. 2018 , 14, 168-181	505
187	Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review. <i>Journal of Neurology</i> , 2018 , 265, 1497-1510	5.5 66
186	Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. 2018 , 136, 251-259	86
185	The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. 2018 , 245, 85-100	127

184	Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. 2018 , 9, 809-816		17
183	Mechanism of intranasal drug delivery directly to the brain. 2018 , 195, 44-52		232
182	Targeting Insulin for Alzheimer's Disease: Mechanisms, Status and Potential Directions. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S427-S453	4-3	14
181	Multifactorial Hypothesis and Multi-Targets for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, S107-S117	4-3	67
180	Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease. 2018 , 83, 347-357		169
179	Intranasal Insulin Ameliorates Cerebral Hypometabolism, Neuronal Loss, and Astroglialosis in Streptozotocin-Induced Alzheimer's Rat Model. 2018 , 33, 716-724		22
178	Alzheimer's disease in humans and other animals: A consequence of postreproductive life span and longevity rather than aging. 2018 , 14, 195-204		44
177	Obesity as a risk factor for Alzheimer's disease: weighing the evidence. 2018 , 19, 269-280		97
176	Shared pathological pathways of Alzheimer's disease with specific comorbidities: current perspectives and interventions. 2018 , 144, 360-389		8
175	Intranasal insulin in Alzheimer's disease: Food for thought. 2018 , 136, 196-201		53
174	Nose-to-brain peptide delivery - The potential of nanotechnology. 2018 , 26, 2888-2905		77
173	Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets. 2018 , 136, 160-171		70
172	Possible Clues for Brain Energy Translation via Endolysosomal Trafficking of APP-CTFs in Alzheimer's Disease. 2018 , 2018, 2764831		5
171	A Ketogenic Diet Improves Cognition and Has Biochemical Effects in Prefrontal Cortex That Are Dissociable From Hippocampus. 2018 , 10, 391		51
170	Intranasal Insulin Prevents Anesthesia-induced Cognitive Impairments in Aged Mice. 2019 , 16, 8-18		14
169	Advances in developing novel therapeutic strategies for Alzheimer's disease. 2018 , 13, 64		116
168	Insulin Resistance in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018 , 12, 830	5-1	94
167	Neuroprotection via AT receptor agonists in ischemic stroke. 2018 , 132, 1055-1067		14

166	A review of brain insulin signaling in mood disorders: From biomarker to clinical target. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 92, 7-15	9	14
165	Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. 2018 , 281, 139-177		228
164	Apolipoprotein E Gene Polymorphisms Affect the Efficacy of Thiazolidinediones for Alzheimer's Disease: A Systematic Review and Meta-Analysis. 2018 , 41, 1017-1023		5
163	Pharmacological and Nonpharmacological Interventions for Cognitive Impairment and Dementia Related to Type 2 Diabetes and Metabolic Disturbances in Aging. 2018 , 231-253		
162	The Role of Insulin Resistance and Signaling in Dementia. 2018 , 143-168		
161	Proteomic Analysis of Hippocampus and Cortex in Streptozotocin-Induced Diabetic Model Mice Showing Dementia. 2018 , 2018, 8953015		2
160	RGC Neuroprotection Following Optic Nerve Trauma Mediated By Intranasal Delivery of Amnion Cell Secretome. 2018 , 59, 2470-2477		14
159	Allogenic Fc Domain-Facilitated Uptake of IgG in Nasal Lamina Propria: Friend or Foe for Intranasal CNS Delivery?. 2018 , 10,		12
158	Alzheimer's Disease: Advances in Drug Development. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 3-13	4-3	32
157	Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review. <i>Frontiers in Neuroscience</i> , 2018 , 12, 215	5.1	50
156	Suppressor of Cytokine Signaling 3: Emerging Role Linking Central Insulin Resistance and Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018 , 12, 417	5.1	15
155	Peptides as Potential Therapeutics for Alzheimer's Disease. 2018 , 23,		32
154	Glucose, Insulin, and Human Brain Aging. 2018 , 889-898		1
153	Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease. 2019 , 56, 2922-2943		47
152	Magnetic drilling enhances intra-nasal transport of particles into rodent brain. 2019 , 469, 302-305		12
151	Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives. 2019 , 33, 957-969		26
150	Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. 2019 , 15, 501-518		322
149	Attenuation of amyloid- β generation by atypical protein kinase C-mediated phosphorylation of engulfment adaptor PTB domain containing 1 threonine 35. 2019 , 33, 12019-12035		7

148	Intranasal Administration of Insulin Reduces Chronic Behavioral Abnormality and Neuronal Apoptosis Induced by General Anesthesia in Neonatal Mice. <i>Frontiers in Neuroscience</i> , 2019 , 13, 706	5.1	12
147	Diabetes Therapies for Dementia. 2019 , 19, 58		10
146	The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease. 2019 , 132, 104541		18
145	. 2019 ,		0
144	Insulin Inhibits A β 2 Aggregation and Prevents A β 2-Induced Membrane Disruption. 2019 , 58, 4519-4529		8
143	Brain Insulin Resistance and Hippocampal Plasticity: Mechanisms and Biomarkers of Cognitive Decline. <i>Frontiers in Neuroscience</i> , 2019 , 13, 788	5.1	67
142	Molecular Mechanisms of Intranasal Insulin in SAMP8 Mice. <i>Journal of Alzheimer's Disease</i> , 2019 , 71, 1361-1373	4.3	36
141	Type 2 Diabetes Mellitus Increases The Risk of Late-Onset Alzheimer's Disease: Ultrastructural Remodeling of the Neurovascular Unit and Diabetic Gliopathy. 2019 , 9,		26
140	The Cognitive Control of Eating and Body Weight: It's More Than What You "Think". 2019 , 10, 62		43
139	Molecular Connection Between Diabetes and Dementia. 2019 , 1128, 103-131		7
138	Diabetes Mellitus. 2019 ,		
137	The Link Between Diabetes, Glucose Control, and Alzheimer's Disease and Neurodegenerative Diseases. 2019 , 89-115		
136	A metabolic perspective of late onset Alzheimer's disease. 2019 , 145, 104255		12
135	Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018. 2019 , 6, 198-203		4
134	Role of the Blood-Brain Barrier in Central Nervous System Insulin Resistance. <i>Frontiers in Neuroscience</i> , 2019 , 13, 521	5.1	75
133	Prospective of managing impaired brain insulin signalling in late onset Alzheimers disease with existing diabetic drugs. 2019 , 18, 229-242		1
132	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). 2019 , 20, 191		57
131	Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. 2019 , 14, e0214364		30

130	ApoE4: an emerging therapeutic target for Alzheimer's disease. 2019 , 17, 64		169
129	Metformin treatment improves the spatial memory of aged mice in an genotype-dependent manner. 2019 , 33, 7748-7757		18
128	Outcomes and clinical implications of intranasal insulin administration to the central nervous system. 2019 , 317, 180-190		23
127	Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 69, 489-498	4.3	34
126	Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer's Disease. 2019 , 11, 88		41
125	REPURPOSING DIABETES DRUGS FOR NEURODEGENERATIVE DISEASES: ANTI-DIABETIC DRUG REPOSITION. 2019 , 9, 81-87		
124	Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease. 2019 , 44, 337-348		16
123	Early-Stage Alzheimer's Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 657-668	4.3	25
122	Hyperinsulinemia or Insulin Resistance: What Impacts the Progression of Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2019 , 72, S71-S79	4.3	12
121	Future Treatment of Alzheimer Disease. 2019 ,		1
120	Intranasal insulin activates Akt2 signaling pathway in the hippocampus of wild-type but not in APP/PS1 Alzheimer model mice. 2019 , 75, 98-108		17
119	The Synergistic Effects of APOE Genotype and Obesity on Alzheimer's Disease Risk. <i>International Journal of Molecular Sciences</i> , 2018 , 20,	6.3	22
118	Routes for the delivery of insulin to the central nervous system: A comparative review. 2019 , 313, 10-15		15
117	Expression of a Constitutively Active Human Insulin Receptor in Hippocampal Neurons Does Not Alter VGCC Currents. 2019 , 44, 269-280		5
116	Long-Term Intranasal Insulin Aspart: A Profile of Gene Expression, Memory, and Insulin Receptors in Aged F344 Rats. 2020 , 75, 1021-1030		6
115	Efficacy of Cholesterol Nose-to-Brain Delivery for Brain Targeting in Huntington's Disease. 2020 , 11, 367-372		11
114	Inhibitory Activity of Insulin on A β Aggregation Is Restricted Due to Binding Selectivity and Specificity to Polymorphic A β States. 2020 , 11, 445-452		12
113	Metabolic Dysregulation Contributes to the Progression of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2020 , 14, 530219	5.1	27

112	Antidiabetic Drugs in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review. 2020 , 49, 423-434		13
111	Characterization of the Meal-Stimulated Incretin Response and Relationship With Structural Brain Outcomes in Aging and Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2020 , 14, 608862	5.1	
110	Role of Insulin in Neurotrauma and Neurodegeneration: A Review. <i>Frontiers in Neuroscience</i> , 2020 , 14, 547175	5.1	13
109	Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease. 2020 , 43, 932-960		4
108	Intranasal Insulin as Promising Therapy for Preserving Pragmatic Competence in MCI and AD. 2020 ,		
107	Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review. 2020 , 11, 560375		15
106	Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience. 2020 , 252, 493-523		12
105	Type 3 Diabetes and Its Role Implications in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	49
104	Neonatal Exposure to Anesthesia Leads to Cognitive Deficits in Old Age: Prevention with Intranasal Administration of Insulin in Mice. 2020 , 38, 299-311		8
103	Brain insulin resistance: role in neurodegenerative disease and potential for targeting. 2020 , 29, 333-348		44
102	Recent Strategies for Targeted Brain Drug Delivery. 2020 , 68, 567-582		7
101	Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention. 2020 , 32, 1188-1236		27
100	Memory advancement by intranasal insulin in type 2 diabetes (MemAID) randomized controlled clinical trial: Design, methods and rationale. 2020 , 89, 105934		11
99	Bioenergetic adaptations to HIV infection. Could modulation of energy substrate utilization improve brain health in people living with HIV-1?. 2020 , 327, 113181		1
98	ApoE and cerebral insulin: Trafficking, receptors, and resistance. 2020 , 137, 104755		20
97	Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders. 2020 , 25,		44
96	Role of Insulin Resistance in the Alzheimer's Disease Progression. 2020 , 45, 1481-1491		20
95	Intranasal Insulin Treatment Attenuates Metabolic Distress and Early Brain Injury After Subarachnoid Hemorrhage in Mice. 2021 , 34, 154-166		4

94	Diabetes-Alzheimer's Disease Link: Targeting Mitochondrial Dysfunction and Redox Imbalance. 2021 , 34, 631-649		10
93	Intranasal delivery of BDNF rescues memory deficits in AD11 mice and reduces brain microgliosis. 2021 , 33, 1223-1238		14
92	Intranasal anti-caspase-1 therapy preserves myelin and glucose metabolism in a model of progressive multiple sclerosis. 2021 , 69, 216-229		4
91	Intranasal Insulin for Alzheimer's Disease. 2021 , 35, 21-37		19
90	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. 2021 , 13, 47		14
89	Intranasal drug delivery for treatment of Alzheimer's disease. 2021 , 11, 411-425		6
88	Dissecting Sex-Related Cognition between Alzheimer's Disease and Diabetes: From Molecular Mechanisms to Potential Therapeutic Strategies. 2021 , 2021, 4572471		3
87	A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnesic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease. 2021 , 38, 407-415		6
86	Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer's disease. 2021 , 33, e12959		9
85	Inflammation and Insulin Resistance as Risk Factors and Potential Therapeutic Targets for Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2021 , 15, 653651	5.1	6
84	Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions. 2021 , 11,		9
83	Intranasal Delivery of Collagen-Loaded Neprilysin Clears Beta-Amyloid Plaques in a Transgenic Alzheimer Mouse Model. 2021 , 13, 649646		2
82	Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders. 2021 , 12, 667874		7
81	Some Candidate Drugs for Pharmacotherapy of Alzheimer's Disease. 2021 , 14,		6
80	Intranasal insulin and orexins to treat age-related cognitive decline. 2021 , 234, 113370		7
79	Multi-scale modeling for systematically understanding the key roles of microglia in AD development. 2021 , 133, 104374		2
78	Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease.. 2022 , 12, 511-531		4
77	Intranasal insulin rescues repeated anesthesia-induced deficits in synaptic plasticity and memory and prevents apoptosis in neonatal mice via mTORC1. 2021 , 11, 15490		1

76	Altered insulin pathway compromises mitochondrial function and quality control both in in vitro and in vivo model systems. 2021 , 60, 178-188		3
75	Alzheimer's Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort. <i>Journal of Alzheimer's Disease</i> , 2021 , 83, 1303-1312	4.3	1
74	Intranasal route: The green corridor for Alzheimer's disease therapeutics. 2021 , 66, 102791		0
73	Intranasal insulin. 2021 , 33, e12934		10
72	Intranasal drug delivery: opportunities and toxicologic challenges during drug development. 2021 , 1		55
71	Metabolic Syndrome as a Risk Factor for Alzheimer Disease. 2013 , 281-341		3
70	Executive Functioning, Visuo-Spatial and Inter-Personal Skill Preservation in Alzheimer's and Mild Cognitive Impairment. 2019 , 373-389		0
69	Central nervous pathways of insulin action in the control of metabolism and food intake. 2020 , 8, 524-534		50
68	Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. 2012 , 122, 1316-38		1101
67	New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders. 2017 , 23, 731-752		21
66	Therapeutic Approaches to Alzheimer's Type of Dementia: A Focus on FGF21 Mediated Neuroprotection. 2019 , 25, 2555-2568		13
65	Cognition in non-demented diabetic older adults. 2012 , 5, 131-5		24
64	Type 3 diabetes (Alzheimer's disease): new insight for promising therapeutic avenues. 2020 , 62, 155-163		4
63	Intranasal Insulin for Alzheimer's Disease and Amnesic Mild Cognitive Impairment: Systematic Review and Meta-analysis. 2017 , 27, 161-170		1
62	Antidiabetic therapies and Alzheimer disease. 2019 , 21, 83-91		18
61	Insulin resistance and reduced brain glucose metabolism in the aetiology of Alzheimer's disease. 2016 , 1,		8
60	New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases. <i>Neural Regeneration Research</i> , 2014 , 9, 1870-3	4.5	20
59	Intranasal insulin neuroprotection in ischemic stroke. <i>Neural Regeneration Research</i> , 2016 , 11, 400-1	4.5	10

- 58 The Role of Insulin Resistance in Age-Related Cognitive Decline and Dementia. **2009**, 433-457
- 57 Diet, Abeta Oligomers and Defective Insulin and Neurotrophic Factor Signaling in Alzheimer's Disease. **2010**, 183-199
- 56 Diabetes Type II: A Risk Factor for Depression-Parkinson-Alzheimer?. **2012**, 153-165
- 55 Brain Insulin Resistance. 139-164
- 54 Carbohydrates, Glucose and Cognitive Performance. **2012**, 139-157
- 53 Hematopoietic Growth Factor Family for Stroke Drug Development. **2012**, 251-276
- 52 Diabetes Type II: A Risk Factor for Depression-Parkinson-Alzheimer?. **2013**, 171-183
- 51 Demenz und Diabetes mellitus. **2013**, 233-247
- 50 Intranasal Delivery of Neuropeptide-Loaded Nanoparticles and Their Application to Nervous System Therapeutics. **2014**, 195-213
- 49 Impairment of Energy Metabolism and Vascular Function in Alzheimer's Disease. **2015**, 219-238
- 48 [Diabetes mellitus and the central nervous system]. **2016**, 88, 82-86 2
- 47 Protective Effects of Exercise and Insulin Against Stress-Induced Impairment of Spatial Learning. **2018**, In Press,
- 46 Systematically understanding the key roles of microglia in AD development.
- 45 Insulin Resistance and Oligodendrocyte/Microvascular Endothelial Cell Dysfunction as Mediators of White Matter Degeneration in Alzheimer's Disease. 123-145
- 44 Effect of Pharmacological and Neurostimulation Interventions for Cognitive Domains in Patients with Bipolar Disorder: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. **2021**, 13, 1039-1049 1
- 43 Pharmacogenomic approaches to the treatment of sporadic Alzheimer's disease. **2020**, 81-94
- 42 A novel bioinformatics approach to reveal the role of circadian oscillations in AD development.
- 41 The Role of Glycaemic Control in Cognitive Functioning. **2021**, 101-134

40	A derangement of the brain wound healing process may cause some cases of Alzheimer's disease. 2016 , 22, 43-6		7
39	Sevoflurane-induced neuronal apoptosis in neonatal mice is prevented with intranasal administration of insulin. 2020 , 12, 8175-8184		1
38	Non-Invasive Strategies for Nose-to-Brain Drug Delivery. 2020 , 10,		2
37	Secondary Prevention of Dementia: Combining Risk Factors and Scalable Screening Technology. <i>Frontiers in Neurology</i> , 2021 , 12, 772836	4.1	2
36	Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors.. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12202	6	2
35	Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives.. <i>Frontiers in Physiology</i> , 2021 , 12, 825816	4.6	2
34	Intranasal neprilysin rapidly eliminates amyloid-beta plaques, but causes plaque compensations: the explanation why the amyloid-beta cascade may fail?. <i>Neural Regeneration Research</i> , 2022 , 17, 1881-1884	4.5	1
33	Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?. <i>Frontiers in Neuroscience</i> , 2022 , 16, 824054	5.1	1
32	Insulin action in the brain: cell types, circuits, and diseases.. <i>Trends in Neurosciences</i> , 2022 ,	13.3	4
31	Cognitive glucose sensitivity-proposing a link between cognitive performance and reliance on external glucose uptake.. <i>Nutrition and Diabetes</i> , 2022 , 12, 10	4.7	1
30	Glucose-lowering drugs, cognition, and dementia: The clinical evidence.. <i>Neuroscience and Biobehavioral Reviews</i> , 2022 , 137, 104654	9	0
29	New Horizons - Cognitive dysfunction associated with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	0
28	In Vitro Comparative Study of Solid Lipid and PLGA Nanoparticles Designed to Facilitate Nose-to-Brain Delivery of Insulin.. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
27	Cognitive disorder and dementia in type 2 diabetes mellitus.. <i>World Journal of Diabetes</i> , 2022 , 13, 319-337	4.7	2
26	Table_1.DOCX. 2019 ,		
25	Table_1.DOCX. 2020 ,		
24	Antidiabetic Drugs in the Treatment of Alzheimer's Disease.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
23	MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial.. <i>Journal of Neurology</i> , 2022 , 1	5.5	1

22	Metabolic Reprogramming of Microglia Enhances Proinflammatory Cytokine Release through EphA2/p38 MAPK Pathway in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022 , 1-15	4.3	0
21	Lipid metabolism and storage in neuroglia: role in brain development and neurodegenerative diseases. <i>Cell and Bioscience</i> , 2022 , 12,	9.8	1
20	Insights for Alzheimer's disease pharmacotherapy and current clinical trials. <i>Neurochemistry International</i> , 2022 , 105401	4.4	0
19	Falling Short: The Contribution of Central Insulin Receptors to Gait Dysregulation in Brain Aging. 2022 , 10, 1923		1
18	Incisionless targeted adeno-associated viral vector delivery to the brain by focused ultrasound-mediated intranasal administration. 2022 , 84, 104277		0
17	Targeting the liver in dementia and cognitive impairment: Dietary macronutrients and diabetic therapeutics. 2022 , 190, 114537		0
16	Role of Impaired Insulin Signaling in the Pathogenesis of Dementia. 2022 , 63-84		0
15	Efficacy of intranasal insulin in improving cognition in mild cognitive impairment or dementia: a systematic review and meta-analysis. 14,		1
14	Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols. 2022 , 14, 1870		1
13	A comprehensive review on carrier mediated nose to brain targeting: emphasis on molecular targets, current trends, future prospects, and challenges. 1-13		0
12	Impaired spatial navigation and age-dependent hippocampal synaptic dysfunction are associated with chronic inflammatory response in db/db mice.		0
11	Insulin stimulates atypical protein kinase C-mediated phosphorylation of the neuronal adaptor FE65 to potentiate neurite outgrowth by activating ARF6-Rac1 signaling. 2022 , 36,		0
10	Therapeutic approaches for improving cognitive function in the aging brain. 16,		1
9	Current Insights on the Use of Insulin and the Potential Use of Insulin Mimetics in Targeting Insulin Signalling in Alzheimer's Disease. 2022 , 23, 15811		0
8	The identities of insulin signaling pathway are affected by overexpression of Tau and its phosphorylation form. 14,		0
7	From Determining Brain Insulin Resistance in a Sporadic Alzheimer's Disease Model to Exploring the Region-Dependent Effect of Intranasal Insulin.		0
6	Preclinical In-Vivo Safety of a Novel Thyrotropin-Releasing Hormone-Loaded Biodegradable Nanoparticles After Intranasal Administration in Rats and Primates. 109158182311526		0
5	Type 2 Diabetes and Alzheimer's Disease: The Emerging Role of Cellular Lipotoxicity. 2023 , 13, 183		2

- 4 How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer's disease risk? A novel integrative model. **2023**, 15,
- 3 Hypoglycemic medicines in the treatment of Alzheimer's disease: Pathophysiological links between AD and glucose metabolism. 14,
- 2 Hormonal regulation of metabolism: Recent lessons learned from insulin and estrogen. **2023**, 137, 415-434
- 1 Geroprotective interventions in the 3xTg mouse model of Alzheimer's disease.